secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001437749-24-024329
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed presents Phase 2a biomarker data at AAIC; neflamapimod reduces plasma GFAP in early DLB
--------------------------------------------------------------------------------

- Poster at AAIC 2024: baseline plasma GFAP highly correlated with CDR-SB dementia severity in DLB patients.
- In early-stage DLB (no AD co-pathology), neflamapimod reduced plasma GFAP by mean 10.6 pg/mL vs placebo increase of 14.1 pg/mL (p=0.04).
- Reduction in GFAP correlated with improvement in CDR-SB in neflamapimod-treated early DLB patients (r=0.54, p=0.04).
- Fully enrolled RewinD-LB Phase 2b trial to report topline primary efficacy results in December 2024.
- Management to participate in fireside chat at Canaccord Genuity 44th Annual Growth Conference on August 13, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924024329/0001437749-24-024329-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924024329/crvo20240801_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-024329

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer